Exploring 3 High Growth Tech Stocks in the US Market

Simply Wall St.

Nov 25

As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2586427218"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2586427218\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2586427218?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2025-11-25 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2586427218","market":"sg","top_or_hot":-1,"title":"Exploring 3 High Growth Tech Stocks in the US Market","media":"Simply Wall St.","content":"<div>\n<p>As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exploring 3 High Growth Tech Stocks in the US Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExploring 3 High Growth Tech Stocks in the US Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-25 19:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CTV","symbol_name":"Innovid","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59","article_id":"2586427218","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-dvax/dynavax-technologies/news/exploring-3-high-growth-tech-stocks-in-the-us-market-59","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2586427218","pubTimestamp":1764068888,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those related to artificial intelligence. In this environment of heightened market activity and shifting economic indicators, identifying high-growth tech stocks requires a keen understanding of innovation trends and the ability to navigate volatility effectively.","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"CTV":"Innovid","BK4009":"广告","BK4023":"应用软件","CTV.AU":"ColorTV Ltd","DVAX":"德纳维制药","BK4139":"生物科技","BK7045":"广告","DSP":"Viant Technology Inc.","VRDN":"Viridian Therapeutics, Inc."},"translate_title":"探索美国市场3只高增长科技股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTV.AU":1,"CTV":1,"DSP":1,"DVAX":1,"VRDN":1},"content_text":"As the U.S. market kicks off a holiday-shortened week with significant gains, investors are buoyed by optimism around potential Federal Reserve rate cuts and a rally in tech stocks, particularly those related to artificial intelligence. In this environment of heightened market activity and shifting economic indicators, identifying high-growth tech stocks requires a keen understanding of innovation trends and the ability to navigate volatility effectively.AdvertisementTop 10 High Growth Tech Companies In The United StatesNameRevenue GrowthEarnings GrowthGrowth RatingADMA Biologics20.01%24.80%★★★★★☆Palantir Technologies27.16%29.98%★★★★★★Sanmina31.01%33.24%★★★★★☆Workday11.16%32.14%★★★★★☆Pelthos Therapeutics47.44%126.65%★★★★★☆Circle Internet Group26.03%84.68%★★★★★☆RenovoRx71.45%71.45%★★★★★☆Zscaler15.80%40.68%★★★★★☆Duos Technologies Group53.36%152.11%★★★★★☆Procore Technologies11.61%116.48%★★★★★☆Click here to see the full list of 74 stocks from our US High Growth Tech and AI Stocks screener.Here we highlight a subset of our preferred stocks from the screener.Viridian Therapeutics (VRDN)Simply Wall St Growth Rating: ★★★★★☆Overview: Viridian Therapeutics, Inc. focuses on discovering, developing, and commercializing treatments for serious and rare diseases with a market cap of approximately $2.90 billion.Operations: Viridian Therapeutics generates revenue primarily from its efforts in discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, amounting to $70.79 million.Viridian Therapeutics, showcasing a remarkable annual revenue growth of 56.3%, significantly outpaces the broader U.S. market's average of 10.4%. This biotech firm is on a trajectory to profitability within three years, buoyed by an impressive forecasted earnings growth rate of 54.1% per annum. Recent pivotal phase 3 trials for its thyroid eye disease treatments—veligrotug and VRDN-003—have met all primary and secondary endpoints, underscoring Viridian's potential in revolutionizing therapeutic options in this domain. The company has also strategically expanded its financial flexibility through recent equity offerings totaling over $251 million, enhancing its ability to sustain ongoing and future clinical developments.Click to explore a detailed breakdown of our findings in Viridian Therapeutics' health report.Understand Viridian Therapeutics' track record by examining our Past report.VRDN Earnings and Revenue Growth as at Nov 2025Viant Technology (DSP)Simply Wall St Growth Rating: ★★★★☆☆Overview: Viant Technology Inc. is an advertising technology company with a market capitalization of $612.47 million.Operations: Viant Technology generates revenue primarily from its Enterprise Technology Platform, which contributes $324.13 million.Viant Technology, with a 13.3% annual revenue growth, is navigating the competitive tech landscape by focusing on innovations in Connected TV (CTV) and programmatic advertising. The company's recent earnings report highlighted a modest increase in sales to $85.58 million for Q3 2025, up from $79.92 million the previous year, reflecting steady market penetration despite a slight dip in net income to $0.996 million from $1.51 million year-over-year. Strategic partnerships, like the new multi-year deal with Molson Coors and integration with Magnite's SpringServe platform, underscore Viant's commitment to enhancing ad delivery and effectiveness across digital formats. These collaborations not only expand Viant’s reach but also solidify its position in driving future growth through direct-to-publisher advertising solutions and advanced data-driven strategies for CTV ecosystems.Unlock comprehensive insights into our analysis of Viant Technology stock in this health report.Review our historical performance report to gain insights into Viant Technology's's past performance.DSP Earnings and Revenue Growth as at Nov 2025Dynavax Technologies (DVAX)Simply Wall St Growth Rating: ★★★★☆☆Overview: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company that specializes in developing and commercializing vaccines both in the United States and internationally, with a market cap of approximately $1.31 billion.Operations: The company generates revenue primarily from the discovery, development, and commercialization of novel vaccines, totaling $330.51 million.Dynavax Technologies has demonstrated robust growth, with a notable 17.7% increase in third-quarter revenue year-over-year, reaching $94.88 million. This performance is bolstered by strategic advancements in its vaccine portfolio, particularly the promising clinical trial outcomes of its shingles vaccine candidate, Z-1018. The company's commitment to innovation is further underscored by its recent $100 million stock repurchase plan, reflecting confidence in its financial health and future prospects. Moreover, Dynavax's forward-looking R&D initiatives are set to enhance its competitive edge in the biotech sector, aligning with industry shifts towards more targeted and efficient healthcare solutions.Navigate through the intricacies of Dynavax Technologies with our comprehensive health report here.Assess Dynavax Technologies' past performance with our detailed historical performance reports.DVAX Revenue and Expenses Breakdown as at Nov 2025Make It HappenDive into all 74 of the US High Growth Tech and AI Stocks we have identified here.Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.Ready For A Different Approach?Explore high-performing small cap companies that haven't yet garnered significant analyst attention.Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.Find companies with promising cash flow potential yet trading below their fair value.  This article by Simply Wall St is general in nature. We provide commentary based on historical data \n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your \n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data. \n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. \n    Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}